Cantuzumab

Cantuzumab
See Cantuzumab mertansine
Wikipedia, the free encyclopedia © 2001-2006 Wikipedia contributors (Disclaimer)
This article is licensed under the GNU Free Documentation License.
Last updated on Friday January 26, 2007 at 14:30:10 PST (GMT -0800)
View this article at Wikipedia.org - Edit this article at Wikipedia.org - Donate to the Wikimedia Foundation

Related Articles
Cantuzumab mertansine and huN901-DM1 advance to proof-of-concept studies.
Feb 04, 2004; 2004 FEB 4 - (NewsRx.com & NewsRx.net) -- ImmunoGen, Inc., (IMGN), a biotechnology company that develops targeted anticancer...
Read more with a free trial on HighBeam.com »
Fiscal year 2002 net loss reported at $0.37 per share.
Sep 18, 2002; 2002 SEP 18 - (NewsRx.com & NewsRx.net) -- ImmunoGen, Inc., (IMGN) announced financial results for the 3 and 12 months ended June...
Read more with a free trial on HighBeam.com »
Relationship with GlaxoSmithKline updated.
Jul 31, 2002; 2002 JUL 31 - (NewsRx.com & NewsRx.net) -- ImmunoGen, Inc., (IMGN), a biopharmaceutical company that develops targeted anticancer...
Read more with a free trial on HighBeam.com »
Research reports on pharmacokinetics from J. Rodon and colleagues provide new insights.
Oct 02, 2008; According to a study from the United States, " Cantuzumab mertansine (SB-408075; huC242-DM1) is a conjugate of the...
Read more with a free trial on HighBeam.com »
ImmunoGen's Stock Dives On Bad News From GSK, Genentech.
Nov 04, 2009; Senior Staff Writer ImmunoGen Inc. made public Monday deflating news that partner GlaxoSmithKline plc does not wish to advance...
Read more with a free trial on HighBeam.com »
HighBeam Research, Inc. © Copyright 2009.

Search another word or see Cantuzumabon Dictionary | Thesaurus |Spanish
  • Please Login or Sign Up to use the Recent Searches feature
FAVORITES
RECENT